NCT05727644已完成1 期
Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0194-0499 in Participants With Various Degrees of Renal Impairment and Normal Renal Function
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- AUC0499,0-∞,SD: Area under the NNC0194-0499 serum concentration-time curve after a single dose
研究概览
简要总结
Novo Nordisk is developing the study medicine NNC0194-0499 for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver. In this study the blood and urine levels of NNC0194-0499 will be compared in people with various degrees of reduced kidney function to the blood and urine levels in people with normal kidney function, after administration of one dose of 30 milligrams (mg) NNC0194-0499. Participant will only get the study medicine in one injection into a skinfold in the thigh (subcutaneous). The study will last for about 66 days including a screening phase of up to 28 days prior to dosing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged 18-80 years (both inclusive) at the time of signing informed consent.
- •Body mass index (BMI) between 18.5-39.9 kilogram per meter square (kg/m2) (both inclusive).
- •Meeting the pre-defined estimated glomerular filtration rate (eGFR) values based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation according to Kidney Disease: Improving Global Outcomes (KDIGO) 20121, 2 standardized to the individual body surface area (BSA).
- •Group description eGFR (mL/min)
- •Normal renal function greater than or equal to 90
- •Mild renal impairment 60 - 89
- •Moderate renal impairment 30 - 59
- •Severe renal impairment 15 - 29 not requiring dialysis
- •End-Stage Renal Disease (ESRD) less than 15 or requiring dialysis treatment Renal group 5 (ESRD).
- •Participants requiring dialysis treatment should be on treatment with haemodialysis.
排除标准
- •Any disorder, except for conditions associated with renal impairment, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
- •Use of prescription medicinal products or non-prescription drugs, or non-routine vitamins, which at the investigators judgement may affect participant safety or the results of the study within 14 days before screening. Use of the following are allowed: Routine vitamins, occasional use of paracetamol, ibuprofen and topical medication not reaching systemic circulation.
- •Use of drugs known to affect creatinine clearance including cephalosporin and aminoglycoside antibiotics, flucytosine, cisplatin, cimetidine, trimethoprim, cibenzoline and nitrofurantoin within 14 days or 5 half-lives, whichever is greater, before planned dosing of the investigational medicinal product (IMP).
- •Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, or endocrinological conditions (except conditions associated with renal impairment or ESRD).
研究组 & 干预措施
Participants with normal renal function
Active Comparator
Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
干预措施: NNC0194-0499 (Drug)
Participants with impaired renal function
Experimental
Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
干预措施: NNC0194-0499 (Drug)
结局指标
主要结局
AUC0499,0-∞,SD: Area under the NNC0194-0499 serum concentration-time curve after a single dose
时间窗: From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 36)
Measured as hours\*nanomoles per litre (h\*nmol/L)
次要结局
- CL/F0499,SD: Apparent clearance of NNC0194-0499 after a single dose(From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 36))
- Cmax,0499,SD: Maximum observed serum NNC0194-0499 concentration after a single dose(From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 36))
- tmax,0499,SD: Time to maximum observed serum NNC0194-0499 concentration after a single dose(From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 36))
- t½,0499,SD: Terminal half-life of NNC0194-0499 after a single dose(From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 36))
- Vz/F0499,SD: Apparent volume of distribution of NNC0194-0499 after a single dose(From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 36))
- CLR,0499,SD: Renal clearance of NNC0194-0499 after a single dose(From baseline (Visit 2, Day 1, predose) until completion of the urine collection period 96 hours after dosing (Visit 2, Day 5))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver FunctionHepatic ImpairmentHealthy VolunteersNCT05917938Novo Nordisk A/S33
已完成
1 期
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionOverweightObesityDiabetes Mellitus, Type 2NCT06559527Novo Nordisk A/S42
已完成
1 期
A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney FunctionDiabetes Mellitus, Type 2NCT05015894Novo Nordisk A/S42
已完成
1 期
A Study of A4368 in Healthy SubjectsHealth SubjectsNCT04932252Autophagy Sciences, Inc.78
已完成
1 期
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After MenopauseDiabetes Mellitus, Type 2NCT05153564Novo Nordisk A/S27